Biotechnology - Genomic and Proteomics: Difference between revisions

From Commons Based Research
Jump to navigation Jump to search
No edit summary
No edit summary
Line 33: Line 33:
Source: [http://www.ibisworld.com/industry/retail.aspx?indid=2001&chid=1 Ibis World]
Source: [http://www.ibisworld.com/industry/retail.aspx?indid=2001&chid=1 Ibis World]


== Market Actors ==


Government:
== Study of the field ==


Universities:
Analysis of the field with basis on [https://cyber.law.harvard.edu/commonsbasedresearch/Field_Research_Methodology Field Research Methodology]


Non-Profits:
# Economics of Intellectual Property in the Biotech- Genomics and Proteomics-(BGP) Field
#*[[Overview of Economics of Intellectual Property in BGP]]
# Overall Picture of the Biotech Field
#*[[Give an overall picture of the BGP field]]
# Outputs and Products of the field
#*[[data, narratives and tools produced by the BGP field]]
# Legal tools available for and in use by the actors of BGP field
#*[[IP in BGP]]
# Competitive advantages in Biotech
#*[[competitive advantages in BGP]]
# Biggest BGP for-profit companies
#*[[IP Profile of Biggest for-profit companies in BGP]]
# Biggest BGP non-profit companies
#*[[IP Profile of non-profit companies in BGP]]
# Most important Universities focused on BGP
#*[[IP Profile of Universities working in BGP]]
#Most important Association in Biotech
#*[[IP Profile of Associations in BGP]]
# Commons based cases in Biotech
#*[[Commons based cases in BGP]]
# New/Open Business Models in Biotech
#*[[Open Business models in BGP]]


For-Profits:
== Resources ==
 
Foundations:
 
[http://www.merck.com/corporate-responsibility/philanthropy/the-merck-company-foundation.html The Merck Foundation]
 
== Funding structure of Actors ==
 
== Actors IP Practices ==
 
== Public Control and the norms controlling the Commons ==


* The case of Foundational Data
=== Cases of Study ===
* The case of observational data
* The case of narratives
* The case of Informatics tools
* The case of Biological Materials


== Possible Cases of Study ==
[[Commons-based cases in BGP]]
[[Open Business models in BGP]]


Industry:
=== Industry Profile ===


Non-Profits:
[[Bibliography on BGP Industry Profile]]


o [http://www.cambia.org/daisy/cambia/home.html CAMBIA / BIOS]
=== Links ===


o [http://www.obofoundry.org Open Biological Ontologies]
[[Links]]


o [http://sciencecommons.org Science Commons]
=== Blogs and news from the BGP field ===


o [http://sciencecommons.org/projects/healthcommons/ Health Commons]
[[Blogs to watch]]


o [http://syntheticbiology.org Synthetic Biology]
=== Interviews ===  
 
o [http://www.biodas.org/wiki/Main_Page Distributed Annotation System]
 
o [www.hapmap.org HapMap]
 
o [http://www.personalgenomes.org Personal Genome Project]
 
o [http://www.genome.gov/10005107 ENCODE]
 
o [http://www.ornl.gov/sci/techresources/Human_Genome/home.shtml Human Genome Project]
 
== Resources ==
 
[[Links on Bio]]
 
[[Bibliography on Bio]]
 
[[Blogs to watch on Bio]]
 
== Interviews ==  


Possible candidates for interviews:
Possible candidates for interviews:


[[GGG]]
[[HHH]]
[[III]]




[[Main Page]]
[[Main Page]]

Revision as of 13:13, 3 March 2009

Field definition

Simply defined, biotechnology is any technology that relies on living organisms or biological systems. By this definition, human beings have been using biotechnology for thousands of years to produce food products, textiles and other necessary items. Several familiar items -- including yeast-rising bread, yogurt, cheese, wine, beer and vinegar -- are all produced with the help of cultured microorganisms.

In recent years, however, the term "biotechnology" has come to mean the use of genetic engineering and its associated techniques. This more common definition is found in a variety of applications, from medicine to agriculture.

The US biotechnology industry includes about 1,000 companies, with combined annual revenue close to $50 billion. Large companies include Amgen, Monsanto, Genentech, and Biogen. The biotechnology and the pharmaceutical industries overlap considerably, since many drugs are now developed using biotechnology. The industry consists of a few very large companies and many very small ones, and is fragmented by type of product. Most companies have annual sales under $50 million.

Industry overview here: Biotechnology Industry Organization

Key Industry Statistics

Key Industry Figures 2008

Industry Revenue *85,695.4$Mil

Revenue Growth *12.9%

Industry Gross Product *58,539.2 $Mil

Number of Establishments *6,815 Units

Number of Enterprises *6,480 Units

Employment *341,000 Units

Exports *7,251$Mil

Imports *2,954.7$Mil

Total Wages *20,630.9$Mil

Source: Ibis World


Study of the field

Analysis of the field with basis on Field Research Methodology

  1. Economics of Intellectual Property in the Biotech- Genomics and Proteomics-(BGP) Field
  2. Overall Picture of the Biotech Field
  3. Outputs and Products of the field
  4. Legal tools available for and in use by the actors of BGP field
  5. Competitive advantages in Biotech
  6. Biggest BGP for-profit companies
  7. Biggest BGP non-profit companies
  8. Most important Universities focused on BGP
  9. Most important Association in Biotech
  10. Commons based cases in Biotech
  11. New/Open Business Models in Biotech

Resources

Cases of Study

Commons-based cases in BGP Open Business models in BGP

Industry Profile

Bibliography on BGP Industry Profile

Links

Links

Blogs and news from the BGP field

Blogs to watch

Interviews

Possible candidates for interviews:


Main Page

Retrieved from "http://cyber.harvard.edu/commonsbasedresearch/?title=Biotechnology_-_Genomic_and_Proteomics&oldid=173"